Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial

CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma

(2019) Christopher R. Marlein et al.   CANCER RESEARCH

Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma

(2018) Felicia Tang et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

CD38-NAD + Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response

(2018) Shilpak Chatterjee et al.   Cell Metabolism

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

(2016) Saad Z. Usmani et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Treatment options for relapsed and refractory multiple myeloma

(2015) A. K. Nooka et al.   BLOOD

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY